Innate pharma has selected a new immuno-modulatory compound for its T gamma-delta platform, IPH 1201.
Entering its pre-clinical and pharmaceutical development, IPH 1201 is intended to be developed in chronic viral infections.
| PR in english | 113.27 KB |
| CP en français | 106.2 KB |